HK1052874B - Compositions containing a naphthalmide and an antiproliferative agent - Google Patents

Compositions containing a naphthalmide and an antiproliferative agent Download PDF

Info

Publication number
HK1052874B
HK1052874B HK03105124.5A HK03105124A HK1052874B HK 1052874 B HK1052874 B HK 1052874B HK 03105124 A HK03105124 A HK 03105124A HK 1052874 B HK1052874 B HK 1052874B
Authority
HK
Hong Kong
Prior art keywords
amonafide
agents
antiproliferative agent
days
saline
Prior art date
Application number
HK03105124.5A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1052874A1 (en
Inventor
Dennis M. Brown
Original Assignee
Chemgenex Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgenex Pharmaceuticals Inc. filed Critical Chemgenex Pharmaceuticals Inc.
Publication of HK1052874A1 publication Critical patent/HK1052874A1/en
Publication of HK1052874B publication Critical patent/HK1052874B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03105124.5A 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent HK1052874B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19710300P 2000-04-12 2000-04-12
US60/197,103 2000-04-12
PCT/US2001/012169 WO2001078705A2 (en) 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent

Publications (2)

Publication Number Publication Date
HK1052874A1 HK1052874A1 (en) 2003-10-03
HK1052874B true HK1052874B (en) 2006-05-04

Family

ID=22728064

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105124.5A HK1052874B (en) 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent

Country Status (10)

Country Link
US (2) US6630173B2 (cg-RX-API-DMAC7.html)
EP (1) EP1274458B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003530431A (cg-RX-API-DMAC7.html)
AT (1) ATE305312T1 (cg-RX-API-DMAC7.html)
AU (1) AU5348301A (cg-RX-API-DMAC7.html)
CA (1) CA2404278C (cg-RX-API-DMAC7.html)
DE (1) DE60113666T2 (cg-RX-API-DMAC7.html)
ES (1) ES2248312T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052874B (cg-RX-API-DMAC7.html)
WO (1) WO2001078705A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267741T3 (es) * 2000-03-15 2007-03-16 Chemgenex Pharmaceuticals, Inc. Composiciones combinadas de alcaloides de cefalotaxina y de los mismos.
EP1274458B1 (en) * 2000-04-12 2005-09-28 ChemGenex Pharmaceuticals, Inc. Compositions containing a naphthalmide and an antiproliferative agent
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
EP1539150A4 (en) * 2002-07-08 2006-10-11 Chemgenex Pharmaceuticals Inc SYNTHESIS OF NAPHTHALIMIDES, INCLUDING AMONAFIDS, AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME
CA2492456A1 (en) * 2002-07-17 2004-01-29 Dennis M. Brown Formulations and methods of administration of cephalotaxines, including homoharringtonine
WO2004009030A2 (en) * 2002-07-22 2004-01-29 Chemgenex Pharmaceuticals Limited Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
JP2007525214A (ja) * 2004-01-30 2007-09-06 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド Ｎ−アセチルトランスフェラーゼ遺伝子型解析によって投与するナフタルイミド
CA2569279A1 (en) * 2004-06-04 2005-12-15 Chemgenex Pharmaceuticals, Inc. Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
CA2597323A1 (en) * 2005-02-10 2006-08-17 Chemgenex Pharmaceuticals, Inc. Medical devices
CA2684219C (en) * 2007-04-13 2017-05-23 Chemgenex Pharmaceuticals, Inc. Oral cephalotaxine dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US5420137A (en) 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
FR2673944B1 (fr) * 1991-03-13 1995-03-10 Sanofi Elf Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
JP2002511878A (ja) * 1997-07-01 2002-04-16 アセロジエニクス・インコーポレイテツド 抗酸化剤による過増殖状態の治療の増強
ES2267741T3 (es) * 2000-03-15 2007-03-16 Chemgenex Pharmaceuticals, Inc. Composiciones combinadas de alcaloides de cefalotaxina y de los mismos.
JP2003531138A (ja) * 2000-03-21 2003-10-21 アセロジエニクス・インコーポレイテツド 生物学的疾患の治療のためのｎ−置換ジチオカルバメート
EP1274458B1 (en) * 2000-04-12 2005-09-28 ChemGenex Pharmaceuticals, Inc. Compositions containing a naphthalmide and an antiproliferative agent

Also Published As

Publication number Publication date
WO2001078705A3 (en) 2002-06-20
DE60113666T2 (de) 2006-06-14
CA2404278A1 (en) 2001-10-25
ATE305312T1 (de) 2005-10-15
ES2248312T3 (es) 2006-03-16
EP1274458A2 (en) 2003-01-15
DE60113666D1 (de) 2005-11-03
WO2001078705A2 (en) 2001-10-25
EP1274458B1 (en) 2005-09-28
HK1052874A1 (en) 2003-10-03
US20040047918A1 (en) 2004-03-11
US20020025916A1 (en) 2002-02-28
JP2003530431A (ja) 2003-10-14
CA2404278C (en) 2010-03-23
US6630173B2 (en) 2003-10-07
AU5348301A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
US20120207855A1 (en) Cephalotaxine alkaloid compositions and uses thereof
EP1274458B1 (en) Compositions containing a naphthalmide and an antiproliferative agent
AU2001245803A1 (en) Cephalotaxine alkaloid compositions and uses thereof
US20020037328A1 (en) Hexitol compositions and uses thereof
US20020040011A1 (en) Naphthoquinone compositions and uses thereof
US20070207977A1 (en) Naphthalimide compositions and uses thereof
AU2001253483B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
AU2006202650B2 (en) Compositions containing a naphthalimide and an antiproliferative agent
US20050170015A1 (en) Antiproliferative colchicine compositions and uses thereof
AU2001253483A1 (en) Compositions containing a naphthalimide and an antiproliferative agent
WO2002056872A2 (en) Antiproliferative colchicine compositions and uses thereof
Linke et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma
HK1052138B (en) Cephalotaxine alkaloid combination compositions and uses thereof
US20020022652A1 (en) Methylnogarol compositions and uses thereof
US20060211648A1 (en) Naphthalimide compositions and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120412